Gall Matthew 4
4 · Kalaris Therapeutics, Inc. · Filed Nov 3, 2025
Insider Transaction Report
Form 4
Gall Matthew
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-11-03+235,000→ 235,000 totalExercise: $4.99Exp: 2035-11-02→ Common Stock (235,000 underlying)
Footnotes (1)
- [F1]The option was granted on November 3, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on November 3, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.